StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price objective on the stock in a research report on Thursday, July 11th.
Read Our Latest Stock Report on Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Stock Up 5.8 %
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. Sell-side analysts expect that Brainstorm Cell Therapeutics will post -0.14 earnings per share for the current year.
Institutional Trading of Brainstorm Cell Therapeutics
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 14.33% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Insider Trading – What You Need to Know
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Why Are Stock Sectors Important to Successful Investing?
- MarketBeat Week in Review – 8/5 – 8/9
- The Most Important Warren Buffett Stock for Investors: His Own
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.